Last updated: April 23, 2026
What is AMICAR and what supplier data can be used to identify upstream manufacturers?
“AMICAR” is a branded name for aminocaproic acid (ACA), an antifibrinolytic used in bleeding disorders. Supplier identification for branded AMICAR depends on (i) the drug substance manufacturer of aminocaproic acid and (ii) the finished-dose manufacturer that produces the marketed tablets/injection under the brand.
A complete, accurate “supplier list” requires authoritative linkage to:
- the approved NDA/ANDA label for the specific AMICAR product and strength (tablet vs injection),
- the finished-dose site(s) listed on the label (manufacturer/distributor),
- and the drug substance manufacturer(s) disclosed in the application and/or regulatory filings (often via FDA databases and/or label manufacturing sections).
No such product-specific regulatory and label-sourced supplier mapping is provided in the input.
Which AMICAR suppliers can be stated from the information provided?
No supplier names, sites, or ownership of AMICAR are provided in the request. Under the operating constraints, a supplier list cannot be produced without label- or database-backed evidence.
What supplier categories exist for AMICAR and how they are typically identified
Even without names, the supplier structure for AMICAR is typically split into:
-
Finished-dose manufacturers (build the final tablet or injection)
Identified via the “Manufactured for” / “Manufactured by” sections on the drug label for the specific dosage form.
-
Drug substance manufacturers (make aminocaproic acid API)
Identified via regulatory disclosures, including FDA-submission materials and sometimes DMF linkages.
-
Distributors / marketers
Identified via the label’s “Distributed by” or “Packaged by” fields.
-
API procurement (contract manufacturing and sourcing agents)
Identified through disclosure in DMF-related references and supply-chain statements, when available in public records.
Actionable implications for R&D and investment workflows
For AMICAR, supplier risk and continuity are driven by API supply and finished-dose packaging bottlenecks. In practice, diligence needs to confirm:
- whether multiple finished-dose sites are listed on the label,
- whether the API has multiple qualified sources (DMF holders),
- and whether supply is domestic vs imported (site and labeling signals).
Key Takeaways
- AMICAR is aminocaproic acid; supplier identification must be label- and regulatory-record anchored to be accurate.
- The prompt provides no product-specific label/manufacturer information, so no verified supplier list can be stated.
- Supplier diligence should separate finished-dose manufacturers, API manufacturers, and distributors, and confirm multi-site qualification.
FAQs
-
Is AMICAR an API-only product or a branded finished drug?
It is a branded finished drug, with the active ingredient aminocaproic acid (API).
-
What counts as a “supplier” for AMICAR due diligence?
The finished-dose manufacturer on the label, the API manufacturer (DMF-linked when available), and the distributor/marketer named on the label.
-
Can API suppliers be inferred from the ingredient name alone?
No. Multiple API sources exist, and only regulatory disclosures tie the correct API supply to the specific marketed product.
-
Does supplier information vary by dosage form?
Yes. Tablet and injection can have different manufacturers and packaging sites.
-
Where does validated supplier data usually come from?
FDA product labeling fields and regulatory submissions/DMF linkages tied to the specific AMICAR listing.
References
[1] FDA. Drug labels and prescribing information (accessed via labeling records for branded products). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] FDA. Drug approvals and submission records (NDA/ANDA context for finished-dose and labeling identifiers). https://www.accessdata.fda.gov/scripts/cder/daf/
